Rapid responses are electronic comments to the editor. They enable our users
to debate issues raised in articles published on bmj.com. A rapid response
is first posted online. If you need the URL (web address) of an individual
response, simply click on the response headline and copy the URL from the
browser window. A proportion of responses will, after editing, be published
online and in the print journal as letters, which are indexed in PubMed.
Rapid responses are not indexed in PubMed and they are not journal articles.
The BMJ reserves the right to remove responses which are being
wilfully misrepresented as published articles or when it is brought to our
attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not
including references and author details. We will no longer post responses
that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
The FDA requires two well-conducted clinical trials demonstrating statistically significant results in favor of a drug for efficacy approval. While this is a permissive standard, the FDA at least adheres to one important element of analysis not strictly enforced by journal editors or in other venues - they require statistical separation in the declared a priori defined primary outcome variables for approval. On the other hand, this request for the FDA to "allow industry to use 'postapproval clinical trials ... post hoc analyses, subpopulation analysis, observational data, real world evidence, and physician treatment guidelines' to support claims about off-label uses" is literally a listing of areas where efficacy has regularly been misreported using "outcome switching" among the many other methods of introducing bias. Given industry's track record over the last several decades, it is the height of hubris to even suggest such changes.